Vaxcyte (PCVX) Research & Development (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Research & Development data on file, last reported at $312.8 million in Q1 2026.

• On a quarterly basis, Research & Development rose 111.15% year-over-year to $312.8 million in Q1 2026; TTM through Mar 2026 was $959.0 million, a 80.87% increase from a year earlier, with the FY2025 full-year figure at $794.3 million, up 66.65% from the prior year.
• Research & Development for Q1 2026 stood at $312.8 million, up from $242.1 million in the prior quarter.
• Over the last five years, Research & Development for PCVX reached as high as $312.8 million in Q1 2026 and fell as low as $31.7 million in Q1 2022.
• Historically, Research & Development has averaged $122.7 million across 5 years, with a median of $104.2 million in 2023.
• Across the five-year window, Research & Development soared 133.4% in 2022 and rose 20.03% in 2024, its largest moves.
• Year by year, Research & Development stood at $51.6 million in 2022, then soared by 101.74% to $104.2 million in 2023, then gained by 28.29% to $133.6 million in 2024, then soared by 81.16% to $242.1 million in 2025, then advanced by 29.22% to $312.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $312.8 million in Q1 2026, $242.1 million in Q4 2025, and $209.9 million in Q3 2025.